Neoadjuvant Chemoradiotherapy Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer: Analysis of Efficacy and Safety in 119 Patients

Dalbagni, 2001, Cystectomy for bladder cancer: a contemporary series, J Urol, 165, 1111, 10.1016/S0022-5347(05)66440-3 Stein, 2001, Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients, J Clin Oncol, 19, 666, 10.1200/JCO.2001.19.3.666 Witjes JA, Bruins HM, Cathomas R, Compérat E, Cowan NC, Efstathiou JA. MIBC_EAU_2021_0409. EAU - Website. Published 2021. Accessed: April 9, 2021, 2021. Available at: http://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/. Griffiths, 2011, International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial, J Clin Oncol, 29, 2171, 10.1200/JCO.2010.32.3139 Grossman, 2003, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer, N Engl J Med, 349, 859, 10.1056/NEJMoa022148 Gore, 2009, Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a surveillance, epidemiology, and end results-medicare analysis, Cancer, 115, 988, 10.1002/cncr.24052 Ghoneim, 1985, Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder, J Urol, 134, 266, 10.1016/S0022-5347(17)47119-9 Ruggeri, 2006, Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies, Cancer, 106, 783, 10.1002/cncr.21676 Spera, 1988, A comparison of preoperative radiotherapy regimens for bladder carcinoma. The university of Pennsylvania experience, Cancer, 61, 255, 10.1002/1097-0142(19880115)61:2<255::AID-CNCR2820610210>3.0.CO;2-X Jiang, 2020, Trimodality therapy for muscle-invasive bladder cancer: recent advances and unanswered questions, Curr Oncol Rep, 22, 14, 10.1007/s11912-020-0880-5 Ploussard, 2014, Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review, Eur Urol, 66, 120, 10.1016/j.eururo.2014.02.038 Kijima, 2019, Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients, BJU Int, 124, 242, 10.1111/bju.14736 Koga, 2009, Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study, BJU Int, 104, 189, 10.1111/j.1464-410X.2008.08297.x Iwai, 2011, Perioperative complications of radical cystectomy after induction chemoradiotherapy in bladder-sparing protocol against muscle-invasive bladder cancer: a single institutional retrospective comparative study with primary radical cystectomy, Jpn J Clin Oncol, 41, 1373, 10.1093/jjco/hyr150 LH, 2009 Mostofi, 1999 Matsuo, 2009, Revised equations for estimated GFR from serum creatinine in Japan, Am J Kidney Dis, 53, 982, 10.1053/j.ajkd.2008.12.034 Kihara, 2015, Gasless single-port robosurgeon surgery in urology, Gasless Single-Port RoboSurgeon Surgery in Urology, 127, 10.1007/978-4-431-54505-7_7 Cancer Institute N. Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events (CTCAE) v5.0.; 2017. Accessed: March 22, 2021, 2021. Available at: https://www.meddra.org/. Clavien, 2009, The clavien-dindo classification of surgical complications: five-year experience, Ann Surg, 250, 187, 10.1097/SLA.0b013e3181b13ca2 Pal, 2012, Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer, Clin Genitourin Cancer, 10, 246, 10.1016/j.clgc.2012.08.004 Pfister, 2022, Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial, J Clin Oncol, 40, 2013, 10.1200/JCO.21.02051 Peyton, 2018, Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer, JAMA Oncol, 4, 1535, 10.1001/jamaoncol.2018.3542 D'Andrea, 2022, Identifying the optimal number of neoadjuvant chemotherapy cycles in patients with muscle invasive bladder cancer, J Urol, 207, 70, 10.1097/JU.0000000000002190 Ferro, 2021, Three vs. four cycles of neoadjuvant chemotherapy for localized muscle invasive bladder cancer undergoing radical cystectomy: a retrospective multi-institutional analysis, Front Oncol, 11, 10.3389/fonc.2021.651745 Mir, 2021, Nomogram predicting bladder cancer–specific mortality after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: results of an international consortium, Eur Urol Focus, 7, 1347, 10.1016/j.euf.2020.07.002 Patel, 2022, Four versus 3 cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: implications for pathological response and survival, J Urol, 207, 77, 10.1097/JU.0000000000002189 Flaig, 2022, Bladder cancer, version 2.2022, J Natl Compr Canc Netw, 20, 866, 10.6004/jnccn.2022.0041 Choi, 2014, Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy, Cancer Cell, 25, 152, 10.1016/j.ccr.2014.01.009 Tanaka, 2018, Impact of immunohistochemistry-based subtypes in muscle-invasive bladder cancer on response to chemoradiation therapy, Int J Radiat Oncol Biol Phys, 102, 1408, 10.1016/j.ijrobp.2018.06.030 Dash, 2006, Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder, Cancer, 107, 506, 10.1002/cncr.22031 Dash, 2008, A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience, Cancer, 113, 2471, 10.1002/cncr.23848 Pfister, 2021, Eur Urol, 79, 214, 10.1016/j.eururo.2020.08.024 Katkoori, 2010, Is the incidence of uretero-intestinal anastomotic stricture increased in patients undergoing radical cystectomy with previous pelvic radiation?, BJU Int, 105, 795, 10.1111/j.1464-410X.2009.08835.x Christodouleas, 2014, Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710, Cancer, 120, 1272, 10.1002/cncr.28544 Iwata, 2019, The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: a systematic review, Urol Oncol Semin Orig Investig, 37, 659 Williams, 2015, Pelvic recurrence after radical cystectomy: a call to arms, BJU Int, 116, 172, 10.1111/bju.12952 Sargos, 2021, Oncologic impact and safety of pre-operative radiotherapy in localized prostate and bladder cancer: a comprehensive review from the cancerology committee of the association française d'urologie, Cancers (Basel), 13, 10.3390/cancers13236070 Kanno, 2020, Oncological outcomes and recurrence patterns after laparoscopic radical cystectomy for bladder cancer: a Japanese multicenter cohort, Int J Urol, 27, 250, 10.1111/iju.14182 Basile, 2022, Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial, Clin Cancer Res, 28, 5107, 10.1158/1078-0432.CCR-22-2158 Bajorin, 2021, Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma, N Engl J Med, 384, 2102, 10.1056/NEJMoa2034442 Fukushima, 2020, Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study, Cancer Med, 9, 8355, 10.1002/cam4.3445 Fukushima, 2021, Combination of cisplatin and irradiation induces immunogenic cell death and potentiates postirradiation anti–PD-1 treatment efficacy in urothelial carcinoma, Int J Mol Sci, 22, 1, 10.3390/ijms22020535